Results 191 to 200 of about 415,375 (309)
Multidimensional predictors of fatigue in amyotrophic lateral sclerosis: a cross-sectional study in China. [PDF]
Cai F +8 more
europepmc +1 more source
The Merits of the Automobile Accident Compensation Plan [PDF]
Lewis, Shippen
core +2 more sources
Severe Juvenile Dermatomyositis With Peripheral Nervous System Involvement: A Case Report. [PDF]
Mora-Bautista VM, Walteros-Cárdenas J.
europepmc +1 more source
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Neurodevelopmental delays in children born after medically assisted reproduction: a national population cohort study. [PDF]
Choe SA +6 more
europepmc +1 more source
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić +4 more
wiley +1 more source
Linkage of Medicare insurance claims to police-reported motor vehicle crashes: advancing traffic safety research in older adult populations. [PDF]
Lu FW +5 more
europepmc +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Predictors of Ability to Work in Multiple Sclerosis. [PDF]
Wellhagen GJ +6 more
europepmc +1 more source
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source

